Mostrar el registro sencillo del ítem

Masitinib for the treatment of mild to moderate Alzheimer's disease

dc.contributor.authorFolch J.
dc.contributor.authorPetrov D.
dc.contributor.authorEttcheto M.
dc.contributor.authorPedrós I.
dc.contributor.authorAbad S.
dc.contributor.authorBeas-Zarate C.
dc.contributor.authorLazarowski A.
dc.contributor.authorMarin M.
dc.contributor.authorOlloquequi J.
dc.contributor.authorAuladell C.
dc.contributor.authorCamins A.
dc.date.accessioned2020-09-02T22:17:54Z
dc.date.available2020-09-02T22:17:54Z
dc.date.issued2015
dc.identifier10.1586/14737175.2015.1045419
dc.identifier.citation15, 6, 587-596
dc.identifier.issn14737175
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4495
dc.descriptionAlzheimer's disease (AD) is a degenerative neurological disorder that is the most common cause of dementia and disability in older patients. Available treatments are symptomatic in nature and are only sufficient to improve the quality of life of AD patients temporarily. A potential strategy, currently under investigation, is to target cell-signaling pathways associated with neurodegeneration, in order to decrease neuroinflammation, excitotoxicity, and to improve cognitive functions. Current review centers on the role of neuroinflammation and the specific contribution of mast cells to AD pathophysiology. The authors look at masitinib therapy and the evidence presented through preclinical and clinical trials. Dual actions of masitinib as an inhibitor of mast cell-glia axis and a Fyn kinase blocker are discussed in the context of AD pathology. Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer. It is also in Phase II/III clinical trials for the treatment of multiple sclerosis, rheumatoid arthritis and AD. Additional research is warranted to better investigate the potential effects of masitinib in combination with other drugs employed in AD treatment. © 2014 Informa UK, Ltd.
dc.language.isoen
dc.publisherExpert Reviews Ltd.
dc.subjectAlzheimer
dc.subjectinflammation
dc.subjectmasitinib
dc.subjectneurodegeneration
dc.subjecttau
dc.subjectmasitinib
dc.subjectstem cell factor receptor
dc.subjectmasitinib
dc.subjectprotein kinase inhibitor
dc.subjectstem cell factor receptor
dc.subjectthiazole derivative
dc.subjectAlzheimer disease
dc.subjectcell interaction
dc.subjectdrug efficacy
dc.subjectdrug mechanism
dc.subjectdrug metabolism
dc.subjectglia cell
dc.subjecthuman
dc.subjectmast cell
dc.subjectnervous system inflammation
dc.subjectnonhuman
dc.subjectpharmacodynamics
dc.subjectphase 1 clinical trial (topic)
dc.subjectphase 2 clinical trial (topic)
dc.subjectphase 3 clinical trial (topic)
dc.subjectReview
dc.subjectAlzheimer disease
dc.subjectanimal
dc.subjectchemistry
dc.subjectmetabolism
dc.subjectAlzheimer Disease
dc.subjectAnimals
dc.subjectHumans
dc.subjectProtein Kinase Inhibitors
dc.subjectProto-Oncogene Proteins c-kit
dc.subjectThiazoles
dc.titleMasitinib for the treatment of mild to moderate Alzheimer's disease
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84930465723.pdf
Tamaño:
3.298Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem